IL2 and neoplasm: PD‐L1 siRNA co‐delivered with the oncogenic transcription factor, signal transducer and activator of transcription‐3 (STAT3) siRNA as specialized nanoparticles were found to constrain tumour growth in murine melanoma and breast cancer models88; IL‐2 siRNA in activated T‐cell/ lung cancer cell coculture models89 and co‐suppression with PD‐1 siRNA demonstrated potent tumour repression in colon cancer mouse xenograft models.90